Equilab International, Indonesian largest Contract Research Organization (CRO) since 2003, specializes in Bioavailability/Bioequivalence Studies, Clinical Trials, Laboratory Testing, and Dermatology Testing. Equilab has completed over 1,000 projects, and collaborated with 85+ international and 120+ domestic customers from Asia, Europe, America, Australia, and Africa. Equilab is a globally recognized CRO that has successfully undergone inspections by the WHO, UK-MHRA, Malaysian NPRA, and BPOM. Our clinical and testing laboratories already accredited ISO/IEC 15189 and ISO/IEC 17025, reflecting our commitment to the highest quality standards and regulatory compliance. Our clinical research reports (CSRs) have been approved by 40+ countries across Asia, Europe, and Africa, including regulatory bodies such as WHO and UK-MHRA. Equilab dedicated to maintain these standards to ensure the utmost integrity and reliability of our research outcomes. As the first CRO in Southeast Asia that is certified by WHO and UK-MHRA, we are in compliance with international GCP and GLP standards. Our study reports have been approved in UK, Netherland, Poland, Spain, Hungary, Afghanistan, Sri Lanka, Bangladesh, Hong Kong, Taiwan, and all Southeast Asia countries. Currently, we are also involved in global trials for Covid-19 vaccine studies. Our existing customers come from Asia, Australia, Africa, America, Europe, and MNC's global.